| Date: | | | 2/3/2023 | | |
|--|---|---|---|---|--|
| Your Name: | | | Konrad Sawicki | | |
| Manuscript Title: | | | Longitudinal Trajectories of Branched Chair Diabetes in Later Life | Amino Acids Through Young Adulthood with | |
| Mai | nuscript Number (if k | (nown): | 166956-INS-CMED-RV-2 | | |
| In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti epidemiology of hypertension, yo that medication is not mentioned | | ipt. "Rela of the man e in doubt os/activition nsion, you entioned | ated" means any relation with for-profit or no nuscript. Disclosure represents a commitment t about whether to list a relationship/activity es/interests should be defined broadly. For early u should declare all relationships with manufin the manuscript. | /interest, it is preferable that you do so. | |
| | | | I entities with whom you have this ship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | | Time frame: Since the initial planning | of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | one 2 HL069771 | Click the tab key to add additional rows. | |
| | | | Time frame: past 36 month | S | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ⊠ No | one | | |
| 3 | Royalties or licenses | ⊠ No | one | | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: \[\text{\$\ti | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | Hongyan Ning |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: \[\text{\$\ti | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | Norrina Allen |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: \[\text{\$\ti | | | |

| ICIVIJE DISCLOSURE FURIVI | | | |
|--|---|--|--|
| Date: | 2/3/2023 | | |
| Your Name: | Mercedes Carnethon | | |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life | | |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 | | |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. | | | |
| The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. | | | |
| In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. | | | |

Name all entities with whom you have this Specifications/Comments (e.g., if payments were made to you or to your institution) relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the None present manuscript (e.g., NIH T32 HL069771 funding, provision of study materials, Click the tab key to add additional rows medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or \times None contracts from any entity (if not indicated in item #1 above). Royalties or \boxtimes None licenses

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: \[\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$ | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | Amisha Wallia |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: \[\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$ | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | James Otvos |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4 | Consulting fees | □ None LabCorp | Consulting fees paid on hourly basis of work performed after Labcorp employment terminated March 31, 2022 |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--|-----|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | Lab | corp | Employment – terminated 3/31/2022 |
| Plea ⊠ | Please place an "X" next to the following statement to indicate your agreement: □ I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | Issam Ben-Sahra |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: Certify that have answered every question and have not altered the wording of any of the questions on this form. | | | |

| | ICMJE DISCLOSURE FORM | | | | | |
|--|---|--|--|--|--|--|
| Date: | 2/3/2023 | | | | | |
| Your Name: | Elizabeth McNally | | | | | |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life | | | | | |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 | | | | | |
| content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned | rt for the work reported in this manuscript without time limit. For all other items, the time | | | | | |
| | | | | | | |

Name all entities with whom you have this Specifications/Comments (e.g., if payments were made to you or to your institution) relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the \boxtimes None present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or None contracts from any entity (if not NIH R01 HL128075, American Heart Association indicated in item SFRN #1 above). 3 Royalties or \boxtimes None licenses

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4 | Consulting fees | □ None Amgen, AstraZeneca, Avidity, Cytokinetics, Janssen, PepGen, Pfizer, Steath Biotherapeutics, and Tenaya Therapeutics | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None | |
| 6 | Payment for expert testimony | None ■ | |
| 7 | Support for attending meetings and/or travel | None ■ | |
| 8 | Patents planned, issued or pending | None ■ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | □ None Editor of JCI Founder, Ikaika Therapeutics | |

| | | | e all entities with whom you have this | Specifications/Comments (e.g., if payments were |
|-----------|--|--------|--|---|
| | | relati | onship or indicate none (add rows as needed) | made to you or to your institution) |
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 2/3/2023 |
|-------------------------------|---|
| Your Name: | Janet Snell-Bergeon |
| Manuscript Title: | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life |
| Manuscript Number (if known): | 166956-INS-CMED-RV-2 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | | ifications/Comments (e.g., if payments were e to you or to your institution) |
|----|--|-----------|--|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: Certify that have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | | | 2/3/2023 | | | |
|---|---|-----------|--|--|--|--|
| Your Name: | | | John Wilkins | | | |
| Manuscript Title: | | | Longitudinal Trajectories of Branched Chain Diabetes in Later Life | Longitudinal Trajectories of Branched Chain Amino Acids Through Young Adulthood with Diabetes in Later Life | | |
| Mai | nuscript Number (if k | nown): | 166956-INS-CMED-RV-2 | | | |
| In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt | | | lated" means any relation with for-profit or no anuscript. Disclosure represents a commitmen | e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. | | |
| epic | | nsion, yo | ou should declare all relationships with manuf | acturers of antihypertensive medication, even if | | |
| | em #1 below, report ne for disclosure is the | | · | ithout time limit. For all other items, the time | | |
| | | | all entities with whom you have this aship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
| | | | Time frame: Since the initial planning | of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | None D1 HL146844 | Click the tab key to add additional rows. | | |
| | | | Time frame: past 36 month | S | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | None | | | |
| 3 | Royalties or licenses | × 1 | None | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4 | Consulting fees | □ None 3M | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None ■ | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|--|---|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: Certify that have answered every question and have not altered the wording of any of the questions on this form. | | | |

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation | Page Number | Relevant Text in Manuscript |
|------------------------------|------------|--|-------------|-----------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 | Lines 56-58 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 | Lines 62-70 |
| Introduction | | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5-6 | Lines 126-154 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 6 | Lines 148-154 |
| Methods | | | | |
| Study design | 4 | Present key elements of study design early in the paper | 16-17 | Lines 378-401 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 16-17 | Lines 378-401 |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants | 16-17 | Lines 378-401 |
| | | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case | 7 | Lines181-184 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 20-21 | Lines 478-493 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 17-18 | Lines 404-426 |
| Bias | 9 | Describe any efforts to address potential sources of bias | | |
| Study size | 10 | Explain how the study size was arrived at | | |

| Quantitative | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe | 20-21 | Lines 478-493 |
|---------------------|----|--|-------|---------------|
| variables | | which groupings were chosen and why | | |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 20-21 | Lines 478-493 |
| | | (b) Describe any methods used to examine subgroups and interactions | 18-19 | Lines 441-461 |
| | | (c) Explain how missing data were addressed | 19 | Lines 454-461 |
| | | (d) Cohort study—If applicable, explain how loss to follow-up was addressed | 16 | Lines 393-398 |
| | | Case-control study—If applicable, explain how matching of cases and controls was | | |
| | | addressed | | |
| | | Cross-sectional study—If applicable, describe analytical methods taking account of | | |
| | | sampling strategy | | |
| | | (e) Describe any sensitivity analyses | 9-10 | 239-240 |

| | | Results | Page Number | Relevant Text in Manuscript |
|------------------------------|-----|---|-------------|-----------------------------|
| Participants 13 | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined | 17 | Line 401 |
| | | for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | | |
| | | (b) Give reasons for non-participation at each stage | 19 | 447-461 |
| | | (c) Consider use of a flow diagram | 7 | 173 |
| Descriptive | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on | 7 | 172-180 |
| data | | exposures and potential confounders | | |
| | | (b) Indicate number of participants with missing data for each variable of interest | 7 | 181-184 |
| | | (c) Cohort study—Summarise follow-up time (eg, average and total amount) | 16 | 378-392 |
| Outcome data 15 ³ | 15* | Cohort study—Report numbers of outcome events or summary measures over time | 30, 33 | DM at Y30 Exam |
| | | Case-control study—Report numbers in each exposure category, or summary measures of exposure | | |
| | | Cross-sectional study—Report numbers of outcome events or summary measures | | |
| Main results 16 | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision | 31, 34 | See table |
| | | (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were | | |
| | | included | | |
| | | (b) Report category boundaries when continuous variables were categorized | 31, 34 | See caption |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time | N/A | N/A |
| | | period | | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 9-10 | 239-240 |
| Discussion | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 11 | 264-275 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. | 14 | 331-346 |
| | | Discuss both direction and magnitude of any potential bias | | |
| Interpretation 2 | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of | 14 | 331-346 |
| | | analyses, results from similar studies, and other relevant evidence | | |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 13 | 319-330 |
| Other informati | ion | | | |
| | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the | 2 | 79-86 |
| | | original study on which the present article is based | | |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.